A look back at this week's news.
Women who underwent a frozen-thawed embryo transfer (FET) for assisted reproductive technology (ART) treatment were nearly twice as likely to experience bleeding or miscarriage in the first trimester with hormone replacement cycles (HRC-FET) compared to natural cycles (NC-FET), according to a retrospective cohort study published in the European Journal of Obstetrics & Gynecology and Reproductive Biology.
What we know so far about remote therapeutic monitoring, remote patient monitoring and preventive services.
Chromosomal abnormalities in infertile couples who use assisted reproductive technology (ART) do not appear to impact cumulative clinical pregnancy or live-birth rates, according to a study published in the Annals of Medicine.
A substudy of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial, which compared three highly effective, reversible methods of contraception, concluded that women assigned either a copper intrauterine device (Cu-IUD) or the levonorgestrel (LNG) implant may have had condomless sex more frequently than women assigned to intramuscular depo-medroxyprogesterone acetate (DMPA-IM).
The US Food and Drug Administration recently updated its guidelines for dispensing mifepristone (the “abortion pill”) to now include certified pharmacies.
Impact of primary care physicians on cervical cancer screening disparities
May 14th 2024A study highlights how having a primary care physician significantly increases the likelihood of cervical cancer screening among lesbian, gay, and bisexual cisgender women, addressing disparities exacerbated by systemic discrimination and healthcare access challenges.
Read More
Prenatal cannabis and nicotine use linked to adverse pregnancy outcomes
May 14th 2024A recent study highlights the heightened risks of maternal and neonatal morbidity and mortality associated with combined cannabis and nicotine use during pregnancy, urging further investigation into their impact on short- and long-term outcomes.
Read More